Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial
Jiwon Lee, Kaylyssa Philip, Hance Clarke, Cheryl Pritlove, Joel Katz, Paul Ritvo, Akash Goel, Muhammad Ishrat Husain, Duminda N Wijeysundera, Karim S Ladha
Canadian Journal of Pain November 8, 2024 DOI: 10.1080/24740527.2024.2406285 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Clinical trial design Peer reviewed |
|---|---|
| Intervention | Psilocybin |
| Topics | Psilocybin |
| Keywords | Neuropathic pain Chronic pain Anesthesia |
| Citations | 3 |
| Key findings | The PEACE-PAIN trial design is supported by patient survey responses but may benefit from modifications, particularly regarding discussions of evidence and adverse effects, and prior psychedelic use among interested participants has methodological implications for inclusion/exclusion criteria. |
Abstract
The PEACE-PAIN trial study design is supported by patient survey responses but may benefit from modifications, namely incorporating thorough discussions of the current evidence for efficacy, safety, tolerability, and approaches to address adverse effects of psilocybin. Additionally, the interest in participation by individuals with prior psychedelic use holds important methodological implications for the inclusion/exclusion criteria of the trial.
Comparable studies
Other non-randomized and open-label trials on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression | 2016 | Open-label feasibility trial | n = 12 |
| Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression | 2017 | Open-label trial | n = 20 |
| Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Psychiatrically healthy nicotine-dependent smokers | 2014 | Open-label pilot study | n = 15 |
| Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression | 2018 | Clinical trial | n = 20 |
| Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) | 2006 | Controlled clinical trial |
Citations in the library
Cited by 3
- The Emergence of Psilocybin in Psychiatry and Neuroscience Pharmaceuticals April 9, 2025
- Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration. International Journal of Molecular Sciences May 9, 2026
- Prospective preference assessment for the Ecstasy for Alleviating Severe Chronic Neuropathic Pain (EASE-Pain) trial. Canadian journal of anaesthesia = Journal canadien d'anesthesie September 1, 2025
Cites 10
- Preparing for the Bursting of the Psychedelic Hype Bubble. JAMA Psychiatry October 1, 2022
- Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology February 1, 2018
- Chronic pain and psychedelics: a review and proposed mechanism of action Regional Anesthesia & Pain Medicine May 4, 2020
- High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology September 1, 2012
- Microdosing psilocybin for chronic pain: a case series Pain September 5, 2022
and 5 more in the library